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With a view to the conflict between patent protection of pharmaceuticals and 
public health, this paper analyzes the ways to balance patent protection of 
pharmaceuticals and public health, and proposes legislative suggestions on the basis 
of realistic situations in China. 
Besides the foreword and conclusion, the dissertation is divided into three 
chapters. 
Chapter one introduces the background of negotiating the TRIPS agreement and 
the international patent protection on pharmaceuticals under the TRIPS agreement. In 
this chapter, the author mainly discusses the influence of pharmaceutical patents on 
public health. Pharmaceutical patents can not significantly increase the R&D on 
diseases which seriously puzzled the poor in developing countries, but allow the 
manufacturer to force up the prices of pharmaceutical products, which limits the 
access to necessary medicines of the poor in developing countries because the prices 
are beyond their payment ability.  
Chapter two analyzes the documents balancing patent protection of 
pharmaceuticals and public health under the WTO regime. Firstly, the chapter 
analyzes flexible provisions for the purpose of protecting public health in the TRIPS 
agreement, such as objectives and principles, exceptions to patent rights, exceptions to 
rights conferred, compulsory licensing, exhaustion of IPR and parallel imports. The 
flexible provisions are very ambiguous and not enough for developing countries to 
serve their national interests in the circumstance of conflict between patent protection 
of pharmaceuticals and protection of public health. Secondly, the chapter analyzes 
another two important documents, namely Doha Declaration on the TRIPS Agreement 
and Public Health adopted in 2001 and Implementation of Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health adopted in 2003. The two 
documents have made some signal achievements for developing countries in the issue 
of balancing patent protection of pharmaceuticals and public health, but they still have 
some defects. To thoroughly resolve this issue, WTO members, especially developing 
countries, should keep on striving. 
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Chapter 3 firstly summarizes the present situation of public health and the access to 
medicine in China., then reviews the history of patent legislation on pharmaceuticals 
in China, and analyzes the insufficiencies of such legislation, and also puts forward 
some corresponding legislative suggestions, according to the TRIPS Agreement, the 
Doha Declaration and the Decision of the General Council . 
 


















WTO World Trade Organization    
世界贸易组织 
WHO World Health Organization    
世界卫生组织 
TRIPS Agreement on Trade-Related Aspects of Intellectual Property Rights
与贸易有关的知识产权协定 
GATT The General Agreement on Tariffs and Trade  
关税与贸易总协定 
UNCTAD United Nations Conference on Trade and Development 
联合国贸易与发展会议 
AIDS Acquired Immune Deficiency Syndrome 
获得性免疫缺陷综合症 
UNAIDS Joint United Nations Programme on HIV/AIDS 
联合国艾滋病规划署 
SARS Severe Acute Respiratory Syndromes  
严重急性呼吸道综合症 
TWN Third World Network   
第三世界网络 


























Table of Cases 案例表 
 
 
Table of Cases 案例表 
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在发展中国家的努力下，WTO 部长会议于 2001 年 11 月在卡塔尔首都多哈
通过了《TRIPS 协定与公共健康多哈宣言》。宣言强调：TRIPS 协定不会也不应
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第一节  TRIPS 协定与药品专利保护 
 
一、TRIPS 协定签订的背景 
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